

# Strategies and Tactics for Successful Partnering 2016



IMS HEALTH  
210 Pentonville Road  
London N1 9JY  
United Kingdom

Tel: +44 (0)20 3075 5888  
Fax: +44 (0)20 3075 5999  
service@imshealth.com  
<http://www.imshealth.com>

The Information Service contained herein is confidential and provided subject to the IMS Health Information Services Standard Terms and Conditions. This Information Service is provided to the client on a personal basis under a non-exclusive and non-transferable license for the Client's own direct benefit and use only, and may not be copied or divulged to any other party. Whilst every possible care has been taken in the preparation of this information, the publishers do not hold themselves responsible for any expressions of opinion or error or omission, or any action resulting therefrom.

© 2016 IMS Health Incorporated or its affiliates. All rights reserved.

## TABLE OF CONTENTS

### EXECUTIVE SUMMARY

#### CHAPTER 1

##### AN INTRODUCTION TO PARTNERING

- 1.1 What is Partnering?
- 1.2 The Partnering Process
- 1.3 Why Do Companies Partner?
- 1.4 Types of Partnering Deal
- 1.5 Who Partners with Whom?
- 1.6 General Trends in Partnering

#### CHAPTER 2

##### WHEN TO PARTNER AND HOW TO FIND THE RIGHT PARTNER

- 2.1 When to Partner
  - 2.1.1 Project Phase
  - 2.1.2 Project Exclusivity
  - 2.1.3 Internal Issues to be Considered
  - 2.1.4 The Final Decision
- 2.2 How to Find the Right Partner
  - 2.2.1 Operational Capabilities
  - 2.2.2 Therapeutic Expertise
  - 2.2.3 Target Partner Profile
  - 2.2.4 Cultural Fit
  - 2.2.5 Ideal and Unsuitable Partners
- 2.3 Partner Identification
  - 2.3.1 Databases
  - 2.3.2 Company Websites
  - 2.3.3 Academic Institutions
  - 2.3.4 General and Industry Press
  - 2.3.5 Regulatory Filings
  - 2.3.6 Personal Contacts
  - 2.3.7 Conferences
  - 2.3.8 Consultants
  - 2.3.9 Internal and External Experts
  - 2.3.10 Unsolicited Approaches
  - 2.3.11 Venture Capitalists
- 2.4 Conclusion

#### CHAPTER 3

##### THE PARTNERING PROCESS

- 3.1 Sequence of Contacts
  - 3.1.1 Initial Approach to Potential Partners
  - 3.1.2 Non-Confidential Information Sent
  - 3.1.3 Internal Review by Partner
  - 3.1.4 Confidential Disclosure Agreement Signed
  - 3.1.5 Confidential Information Supplied
  - 3.1.6 Due Diligence
  - 3.1.7 Deal Terms Agreed
  - 3.1.8 Contract Negotiated
  - 3.1.9 Alliance Management
- 3.2 Non-Confidential Information
- 3.3 Confidential Disclosure Agreement
  - 3.3.1 One-Way or Mutual
  - 3.3.2 Duration
  - 3.3.3 Project Coverage
  - 3.3.4 People Covered
  - 3.3.5 Information Covered
  - 3.3.6 Return of Confidential Information
  - 3.3.7 Public Disclosure
- 3.4 Confidential Information
  - 3.4.1 Cover Sheet
  - 3.4.2 Summary Overview
  - 3.4.3 Scientific Rationale
  - 3.4.4 Therapeutic Rationale
  - 3.4.5 Chemistry, Manufacturing and Control
  - 3.4.6 Technologies and Drug Delivery Systems

- 3.4.7 Preclinical Data
- 3.4.8 Clinical Data
- 3.4.9 Regulatory Status
- 3.4.10 Pre-Marketing Activity
- 3.4.11 Trade Marks
- 3.4.12 Commercial Rationale
- 3.4.13 Patents
- 3.4.14 Future Plans
- 3.4.15 Licensing/Partnership Opportunity
- 3.4.16 Disputes
- 3.4.17 References
- 3.4.18 Marketed Products
- 3.5 Corporate Presentation
  - 3.5.1 Company Background
  - 3.5.2 Major Product Summaries
  - 3.5.3 Sales Infrastructure
  - 3.5.4 R&D Overview
  - 3.5.5 Financials
  - 3.5.6 Licensing
  - 3.5.7 Current Agreements
  - 3.5.8 Partnering Strengths
- 3.6 Managing Your Contacts

#### **CHAPTER 4**

#### **DEALING WITH A MAJOR PHARMACEUTICAL COMPANY**

- 4.1 Background
  - 4.1.1 Initial Approach
  - 4.1.2 Making the Right Contact
- 4.2 The Decision-making Process
  - 4.2.1 Initial Review
  - 4.2.2 Detailed Review
  - 4.2.3 Due Diligence
  - 4.2.4 Valuation
  - 4.2.5 Negotiation
  - 4.2.6 Approval Levels and Committees
- 4.3 Timings
- 4.4 Culture

#### **CHAPTER 5**

#### **DEALING WITH A SMALL BIOTECHNOLOGY COMPANY**

- 5.1 Background
  - 5.1.1 Initial Approach
- 5.2 The Decision-Making Process
  - 5.2.1 Initial Review
  - 5.2.2 Detailed Review
  - 5.2.3 Due Diligence
  - 5.2.4 Valuation
  - 5.2.5 Negotiation
  - 5.2.6 Approval Levels
- 5.3 Timings
- 5.4 Culture

#### **CHAPTER 6**

#### **ESTABLISHING YOUR ORGANISATION AS THE PARTNER OF CHOICE**

- 6.1 Different Partners of Choice for Different Projects
- 6.2 Characteristics of a Partner of Choice
- 6.3 Strategic Fit
- 6.4 Internal Inefficiencies
- 6.5 The Importance of Alliance Management
- 6.6 Promoting Your Capabilities

#### **CHAPTER 7**

#### **VALUATION**

- 7.1 Combining Valuation Techniques
- 7.2 Benchmarking
  - 7.2.1 Feasibility
  - 7.2.2 Data Gathering
  - 7.2.3 Refinement of the Valuation
- 7.3 Expected Net Present Value
  - 7.3.1 Opportunity Cost/Time Value

- 7.3.2 Risk
- 7.3.3 Decision Tree Analysis
- 7.3.4 Sensitivity Analysis
- 7.3.5 Monte-Carlo Simulation
- 7.4 Value Distribution
  - 7.4.1 Value of Deal Components
  - 7.4.2 Value Splits

## **CHAPTER 8 DEAL STRUCTURE**

- 8.1 Evolution of Partnerships
- 8.2 Licensing Agreements
  - 8.2.1 Simple Licensing Agreements
- 8.3 Collaborative R&D Agreements
- 8.4 Evaluation Agreements
- 8.5 Technology Access Agreements
- 8.6 Co-marketing and Co-promotion Agreements
- 8.7 Marketing Agreements
- 8.8 Product Sale and Purchase Agreements
- 8.9 Option Agreements
  - 8.9.1 Option to Purchase
  - 8.9.2 Option to License
- 8.10 Equity Investments
- 8.11 Alternative Deal Structures
  - 8.11.1 Drug Royalty Companies
  - 8.11.2 Risk Sharing Agreements with Contract Research Organisations
  - 8.11.3 Quids
  - 8.11.4 Joint Ventures
- 8.12 Conclusion

## **CHAPTER 9 SECURING THE DEAL**

- 9.1 The Due Diligence Process
- 9.2 The Elements of Due Diligence
- 9.3 Providing the Information
- 9.4 Negotiation
- 9.5 Preparation Phase
- 9.6 Negotiation Phase
  - 9.6.1 Negotiating the Term Sheet and the Financial Terms
  - 9.6.2 Negotiation Behaviour
- 9.7 Outcome Phase

## **CHAPTER 10 THE DEAL LIFE CYCLE**

- 10.1 Alliance Management
- 10.2 Process Risk and Performance Risk
- 10.3 Alliance Life Cycle Model
  - 10.3.1 Negotiation
  - 10.3.2 Formation
  - 10.3.3 Management
  - 10.3.4 Termination
- 10.4 Alliance Management Structure
- 10.5 The Role of the Alliance Manager
- 10.6 Key Factors for Success
  - 10.6.1 Governance
  - 10.6.2 Communication
  - 10.6.3 Alliance Start-Up
  - 10.6.4 Process Integration
- 10.7 Performance Management in Collaborations
- 10.8 Conflict Management
  - 10.8.1 Anticipate and Prepare
  - 10.8.2 Intervene Early
  - 10.8.3 Take Appropriate Remedial Action
- 10.9 Mediation and Arbitration
- 10.10 Litigation
- 10.11 Termination Clauses

**FIGURES**

- Figure 1.1 The deal process chain.
- Figure 1.2 Rate of development of new drugs
- Figure 1.3 Capital raised by biotechnology companies in North America and Europe per year.
- Figure 1.4 R&D stage agreements.
- Figure 1.5 Product licensing agreements.
- Figure 1.6 Joint venture activity, 2011 to 2015
- Figure 1.7 Company type combinations involved in dealmaking, 2011 to 2015.
- Figure 1.8 Biotech-biotech dealmaking activity, 2011 to 2015.
- Figure 1.9 Global-global company dealmaking activity, 2011 to 2015.
- Figure 1.10 Number of deals 2011 to 2015 (excluding funding awards).
- Figure 2.1 Number of all deals by phase of development for deals from 2006 to 2015.
- Figure 2.2 Average total deal values and average upfront payments for product deals by phase of development for deals from 2006 to 2015.
- Figure 2.3 Capabilities across the R&D cycle.
- Figure 2.4 Key areas for relationship fit.
- Figure 2.5 The partner search.
- Figure 3.1 Contact sequence.
- Figure 7.1 Integrated valuation methods
- Figure 7.2 Ideal benchmarking deal cluster.
- Figure 7.3 Non-ideal benchmarking deal cluster.
- Figure 7.4 Example pharmaceutical deal valuation force field.
- Figure 7.5 Attrition by phase and therapeutic area.
- Figure 7.6 Pharmaceutical product decision tree.
- Figure 7.7 The effect of time and risk on the value of deal components.
- Figure 9.1 The term of the working relationship
- Figure 9.2 The negotiation team.
- Figure 9.3 Negotiation styles.
- Figure 10.1 Risks inherent in collaborations.
- Figure 10.2 The four phases of the alliance management life cycle.
- Figure 10.3 The roles of an alliance manager.
- Figure 10.4 Relationship between substantive conflict and interest.

**TABLES**

- Table 1.1 Selected biotech companies raising >US\$100 M in 2015.
- Table 2.1 Issues to consider when out-licensing and in-licensing a project.
- Table 2.2 Checklist of questions to help evaluate in-licensing projects.
- Table 2.3 Target Partner Profile.
- Table 2.4 Corporate culture issues.
- Table 3.1 Contents of a non-confidential document.
- Table 6.1 Successful alliance fitness test.
- Table 7.1 Overview of benchmarking methodology.
- Table 8.1 Reasons a company would out-license or in-license a product.
- Table 8.2 The positives and negatives to consider when entering into co-marketing agreements.
- Table 8.3 The positives and negatives to consider when entering into co-promotion agreements.
- Table 8.4 The positives and negatives to consider when entering into marketing agreements.
- Table 8.5 The positives and negatives to consider in option to license deals.
- Table 9.1 Key areas for consideration in a due diligence exercise.